Can Mexico Medical Device Registration Test Reports Be Reused?

Yes, test reports from other markets (e.g., NMPA, CE, FDA) can often be reused for Mexico registration, but only after confirming product risk classification, applicable regulatory pathway, and evidence consistency. AIMEILI recommends conducting a gap assessment before submission to avoid delays caused by unclear classification or documentation.

Key Considerations

Product Classification and Pathway

Determine the product's intended use, mechanism, sterility, active/in vitro diagnostic status, and risk class to identify the correct registration pathway in Mexico (e.g., COFEPRIS). A wrong classification leads to rework.

Evidence Chain Consistency

Ensure technical files, quality system certificates (e.g., ISO 13485), test reports, clinical evaluation, and labeling are consistent across all claims. Inconsistencies in model coverage, intended use, or warnings often trigger supplemental requests.

Common Mistakes

• Directly translating NMPA files without aligning evidence to Mexico requirements.
• Insufficient test report or clinical evidence coverage for multiple models.
• Selecting a local agent based solely on sales capability without clarifying regulatory responsibilities (e.g., certificate control, post-market obligations).
• Discrepancies between labeling, promotional materials, and registration dossiers.
• Failing to plan for multi-country reuse, causing repeated costs.

Preparation Checklist

Before initiating a Mexico registration project, verify the following:

• Product list with model matrix and intended use.
• Reusability of existing NMPA, CE, or FDA dossiers.
• ISO 13485 certificate, test reports, risk management, clinical evaluation, and English labeling.
• Local agent/authorized representative roles, fees, and certificate control.
• Gap assessment for additional tests, translations, notarizations, or declarations.

AIMEILI Regulatory Interpretation

AIMEILI perspective: Mexico registration should be managed as a market access project, not a document submission. Companies entering multiple GHWP member states should establish a core technical file and evidence matrix for reuse, then localize per country. The three most critical controls are: (1) correct classification and pathway; (2) evidence chain consistency; (3) clear regulatory responsibilities of local partners. Early gap assessment and evidence alignment reduce rework risks and support post-market maintenance.

Business Impact

Efficient report reuse lowers registration costs and timelines by 30–50% for standard devices. However, failure to plan for evidence consistency and local agent accountability can lead to prolonged cycles (6–12 months additional) and loss of market control. Integrating Mexico into a multi-country regulatory strategy enables scalable compliance and faster expansion across Latin America and GHWP markets.